530 related articles for article (PubMed ID: 15009722)
1. Imatinib mesylate inhibits platelet-derived growth factor receptor phosphorylation of melanoma cells but does not affect tumorigenicity in vivo.
McGary EC; Onn A; Mills L; Heimberger A; Eton O; Thomas GW; Shtivelband M; Bar-Eli M
J Invest Dermatol; 2004 Feb; 122(2):400-5. PubMed ID: 15009722
[TBL] [Abstract][Full Text] [Related]
2. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
Irsan I; Akisue T; Hara H; Fujimoto T; Imabori M; Doita M; Kuroda R; Fujioka H; Kawamoto T; Yamamoto T; Kurosaka M
Anticancer Res; 2007; 27(1A):423-9. PubMed ID: 17352263
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model.
Hwang RF; Yokoi K; Bucana CD; Tsan R; Killion JJ; Evans DB; Fidler IJ
Clin Cancer Res; 2003 Dec; 9(17):6534-44. PubMed ID: 14695158
[TBL] [Abstract][Full Text] [Related]
4. Predicting Effectiveness of Imatinib Mesylate in Tumors Expressing Platelet-Derived Growth Factors (PDGF-AA, PDGF-BB), Stem Cell Factor Ligands and Their Respective Receptors (PDGFR-α, PDGFR-β, and c-kit).
Moawad EY
J Gastrointest Cancer; 2015 Sep; 46(3):272-83. PubMed ID: 25985771
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
Haberler C; Gelpi E; Marosi C; Rössler K; Birner P; Budka H; Hainfellner JA
J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
[TBL] [Abstract][Full Text] [Related]
6. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
[TBL] [Abstract][Full Text] [Related]
7. Expression of the platelet-derived growth factor receptor in prostate cancer and treatment implications with tyrosine kinase inhibitors.
Hofer MD; Fecko A; Shen R; Setlur SR; Pienta KG; Tomlins SA; Chinnaiyan AM; Rubin MA
Neoplasia; 2004; 6(5):503-12. PubMed ID: 15548358
[TBL] [Abstract][Full Text] [Related]
8. Improving chemotherapeutic drug penetration in melanoma by imatinib mesylate.
Ogawa Y; Kawamura T; Furuhashi M; Tsukamoto K; Shimada S
J Dermatol Sci; 2008 Sep; 51(3):190-9. PubMed ID: 18485676
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571.
McGary EC; Weber K; Mills L; Doucet M; Lewis V; Lev DC; Fidler IJ; Bar-Eli M
Clin Cancer Res; 2002 Nov; 8(11):3584-91. PubMed ID: 12429650
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate (Gleevec) inhibits ovarian cancer cell growth through a mechanism dependent on platelet-derived growth factor receptor alpha and Akt inactivation.
Matei D; Chang DD; Jeng MH
Clin Cancer Res; 2004 Jan; 10(2):681-90. PubMed ID: 14760091
[TBL] [Abstract][Full Text] [Related]
11. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ
J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice.
Lev DC; Kim SJ; Onn A; Stone V; Nam DH; Yazici S; Fidler IJ; Price JE
Clin Cancer Res; 2005 Jan; 11(1):306-14. PubMed ID: 15671560
[TBL] [Abstract][Full Text] [Related]
13. Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumor of the pleura.
De Pas T; Toffalorio F; Colombo P; Trifirò G; Pelosi G; Vigna PD; Manzotti M; Agostini M; de Braud F
J Thorac Oncol; 2008 Aug; 3(8):938-41. PubMed ID: 18670317
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB.
Aoki M; Nabeshima K; Koga K; Hamasaki M; Suzumiya J; Tamura K; Iwasaki H
Lab Invest; 2007 Aug; 87(8):767-79. PubMed ID: 17558420
[TBL] [Abstract][Full Text] [Related]
15. Imatinib mesylate inhibits platelet-derived growth factor activity and increases chemosensitivity in feline vaccine-associated sarcoma.
Katayama R; Huelsmeyer MK; Marr AK; Kurzman ID; Thamm DH; Vail DM
Cancer Chemother Pharmacol; 2004 Jul; 54(1):25-33. PubMed ID: 15108021
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate inhibits cell growth of malignant peripheral nerve sheath tumors in vitro and in vivo through suppression of PDGFR-β.
Ohishi J; Aoki M; Nabeshima K; Suzumiya J; Takeuchi T; Ogose A; Hakozaki M; Yamashita Y; Iwasaki H
BMC Cancer; 2013 May; 13():224. PubMed ID: 23642185
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells.
Yamaguchi SI; Ueki A; Sugihara E; Onishi N; Yaguchi T; Kawakami Y; Horiuchi K; Morioka H; Matsumoto M; Nakamura M; Muto A; Toyama Y; Saya H; Shimizu T
Cancer Sci; 2015 Jul; 106(7):875-82. PubMed ID: 25940371
[TBL] [Abstract][Full Text] [Related]
18. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.
Wyman K; Atkins MB; Prieto V; Eton O; McDermott DF; Hubbard F; Byrnes C; Sanders K; Sosman JA
Cancer; 2006 May; 106(9):2005-11. PubMed ID: 16565971
[TBL] [Abstract][Full Text] [Related]
19. Chemosensitization by STI571 targeting the platelet-derived growth factor/platelet-derived growth factor receptor-signaling pathway in the tumor progression and angiogenesis of gastric carcinoma.
Kim R; Emi M; Arihiro K; Tanabe K; Uchida Y; Toge T
Cancer; 2005 May; 103(9):1800-9. PubMed ID: 15786421
[TBL] [Abstract][Full Text] [Related]
20. The effect of imatinib mesylate (Glivec) on human tumor-derived cells.
Knight LA; Di Nicolantonio F; Whitehouse PA; Mercer SJ; Sharma S; Glaysher S; Hungerford JL; Hurren J; Lamont A; Cree IA
Anticancer Drugs; 2006 Jul; 17(6):649-55. PubMed ID: 16917210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
